Cancer Genetics, Inc., a diagnostics company focused on developing genomic-based oncology tests and services, has received a formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering a panel of probes for use in its proprietary methods for the detection and differentiation of kidney cancer.
The USPTO issued formal Notice of Allowance to Cancer Genetics for its patent application “Panel for the Detection and Differentiation of Renal Cortical Neoplasms.” Among other things, the patent covers a panel of probes that are used in CGI’s proprietary methods for the detection and differentiation of kidney cancer. These methods were validated through large studies performed in collaboration with Memorial Sloan-Kettering Cancer Center and The Cleveland Clinic. The company expects the patent to be issued and a patent number assigned within the next 60 days.
CGI’s application covers a method for detecting the subtype of renal cortical neoplasm by assessing 19 genomic biomarkers that are associated with certain subtypes of kidney cancer. Using an algorithm developed by CGI, the analysis of these genomic abnormalities allows for an accurate diagnosis of the four main types of kidney cancers, representing approximately 90% of all cases, and the ability to distinguish among benign and malignant sub-types. Read about a proprietary microarray for kidney cancer recently launched by Cancer Genetics.